复方孕二烯酮(Ethinyl Estradiol/Gestodene) - 药物靶点：ER x PR_在研适应症：避孕_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Compound Gestodene、Ethinylestradiol/Gestodene、炔雌醇/孕二烯酮

+ [19]

靶点

ER x PR

作用机制

ERs激动剂(雌激素受体家族激动剂)、PR激动剂(孕激素受体激动剂)

治疗领域

其他疾病

在研适应症

避孕

非在研适应症-

原研机构

Bayer AG

在研机构

Wyeth Australia Pty Ltd.

非在研机构

华润紫竹药业有限公司

最高研发阶段批准上市

首次获批日期

中国 (1998-01-01),

避孕

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C41H50O4

InChIKeyWNSDZLZVSSOOCA-WOMZHKBXSA-N

CAS号109852-02-0

关联

8

项与复方孕二烯酮相关的临床试验

NCT03890042 / CompletedN/AIIT

Dienogest Versus a Low-dose Combined Oral Contraceptive for Treatment of Adenomyotic Uteri

Adenomyosis is a common disease in women aged 40-50 years. It associates with dysmenorrhea and menorrhagia. Hysterectomy was considered the main treatment that could definitively cure this disease. Other treatment options are increasingly offered, including hormonal suppression with gonadotropin-releasing hormone agonists or danazol and endometrial ablation. However, deep adenomyosis responds weakly to the above treatment options, which are commonly not considered for long-term management because of the associated side effects.
Dienogest is a progestin medication which is used in birth control pills and in the treatment of endometriosis and adenomyosis. Low-dose combined oral contraceptive (COC) pills have been widely used as the primary treatment for menorrhagia. COCs can also be used to induce endometrial atrophy and to decrease endometrial prostaglandin production, which can consequently improve menorrhagia and dysmenorrhea that are associated with adenomyosis

开始日期2019-03-01

申办/合作机构

Assiut University

NCT03881904 / Unknown status临床1/2期IIT

Oral Contraceptive Pill Pretreatment in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Using the Gonadotrophin Releasing Hormone Antagonist Protocol (A Randomized Controlled Trial)

373 women with PCOS undergoing a trial of IVF/ICSI will receive OCP from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.
Another 373 women with PCOS undergoing a trial of IVF/ICSI will start GnRH antagonist COH directly without OCP pretreatment.
Both groups will be followed up for effect on ongoing pregnancy rate.

开始日期2017-06-01

申办/合作机构

Ain Shams University

NCT03531437 / Terminated临床4期IIT

Comparison of Coagulation Profiles in Oral Contraceptive Pills Users Between 1.5 mg Estradiol/2.5 mg Nomegestrol Acetate (Zoely) and 15 mcg Ethinylestradiol/60 mcg Gestodene (Minidoz): A Randomized Control Trial

The purpose of this study is to compare the effects of Zoely® and Minidoz® on hemostatic profiles

开始日期2016-03-01

申办/合作机构

Mahidol University

100 项与复方孕二烯酮相关的临床结果

登录后查看更多信息

100 项与复方孕二烯酮相关的转化医学

登录后查看更多信息

100 项与复方孕二烯酮相关的专利（医药）

登录后查看更多信息

52

项与复方孕二烯酮相关的文献（医药）

2016-05-01·Journal of Adolescent Health2区 · 医学

Impact of a Mobile E-Health Intervention on Binge Drinking in Young People: The Digital–Alcohol Risk Alertness Notifying Network for Adolescents and Young Adults Project

2区 · 医学

Article

作者: Francesco Bartoli ; Alessandro Schivalocchi ; Cristina Crocamo ; Giuseppe Carrà ; Massimo Clerici ; Paul E. Bebbington ; Daniele Carretta

PURPOSEBinge drinking (BD) is common among young people. E-Health apps are attractive to them and may be useful for enhancing awareness. We aimed to investigate the impact of a publicly available evidence-based e-Health app (Digital-Alcohol Risk Alertness Notifying Network for Adolescents and Young Adults [D-ARIANNA]), estimating current risk of BD by questions, matching identified risk factors, and providing in percent an overall risk score, accompanied by appropriate images showing mostly contributing factors in summary graphics.METHODSA natural, quasi-experimental, pre-/post-test study was conducted. Subjects were recruited in pubs, clubs, discos, or live music events. They were requested to self-administer D-ARIANNA and were re-evaluated after two further weeks.RESULTSYoung (18-24 years) people (N = 590) reported reduced BD at follow-up (18% vs. 37% at baseline). To exclude systematic errors involving those lost at follow-up (14%), the diminution in BD was confirmed in an appropriate generalized estimating equation model with unweighted data on a last observation carried forward basis.CONCLUSIONSOur study provides evidence of population-level benefit at 2 weeks, attained with D-ARIANNA. This can be disseminated easily and economically among young people. However, additional components, including regular feedback and repeated administration by gamification, may be required to make this app suitable for longer term impact.

2015-04-01·Journal of Family Planning and Reproductive Health Care

The bitter pill

Article

作者: Cox, Lucy

The opinion of Marion Larat is that “nobody, but nobody should take the third- and fourth-generation pills”.1 This view is not surprising as she suffered a devastating stroke at the age of 18 years.2 A subsequent enquiry linked her cerebral vascular accident to Meliane®,3 a 20 μg pill containing gestodene that she had been prescribed for contraception. In December 2012, Marion Larat successfully sued the manufacturer, Bayer, and the French drug regulatory board Agence national de securite du medicament et des produits de sante (ANSM) for damages. Her case was widely publicised in the media and 30 similar lawsuits soon followed. In January 2013, the Minister for Health, Marisol Touraine, announced that France's social security system would no longer reimburse prescriptions for third- and fourth-generation pills.4 At the time around half of the five million French women on the combined pill were taking such pills,5 which cost more to the state than older formulations. Plans were made to strip midwives and nurses of their pill-prescribing powers.5 The ANSM advised that third- and fourth-generation pills should never be used as first-line contraception and should only be prescribed if an older formulation had not been tolerated.5 The ANSM then referred the matter to the European Medicines Agency (EMA) for further investigation. Since the introduction of the combined oral contraceptive pill (COC) in the 1960s, an association between ethinylestradiol (EE) and venous thromboembolism (VTE) has been apparent. The amount of EE in pills has lessened over time to reduce thrombotic potential as well as estrogenic side effects. Older pills contain testosterone-derived progestogens and can have androgenic side effects. Newer formulations have been developed that contain less androgenic progestogens and so aim for better tolerability. Progestogens have been arbitrarily categorised into ‘generations’ based on their chemical structure …

2011-02-01·Scandinavian Journal of Medicine & Science in Sports2区 · 医学

Effect of administration of oral contraceptives on the synthesis and breakdown of myofibrillar proteins in young women

2区 · 医学

Article

作者: T. Trappe ; M. Kjaer ; S. G. Petersen ; B. F. Miller ; M. Hansen ; L. Holm ; D. Skovgaard ; H. Langberg ; S. Doessing

Oral contraceptive (OC) treatment has an inhibiting effect on protein synthesis in tendon and muscle connective tissue. We aimed to investigate whether OC influence myofibrillar protein turnover in young women. OC‐users (24±2 years; Lindynette®n=7, Cilest®n=4) and non‐OC‐users (controls, 24±4 years n=12) performed one‐legged kicking exercise. The next day, the myofibrillar protein fractional synthesis rate (FSR) was measured using stable isotopic tracers (13C‐proline) while the subjects were fed standardized nutrient drinks. Simultaneously, a marker for myofibrillar protein breakdown, 3‐methyl‐histidine (3‐MH), was measured in the interstitial fluid of the vastus lateralis. Measurements were performed in both legs. In general, myofibrillar protein FSR was lower in OC‐users (two‐way analysis of variance, P<0.05), although the difference seemed to depend on the OC type. Interstitial 3‐MH in the skeletal muscle was not different between groups and did not vary by OC type. Exercise did not change myofibrillar protein FSR or 3‐MH concentrations. Serum androstenedione and bioavailability of testosterone were lower in OC‐users. In conclusion, the results indicate that the use of OC has an inhibiting effect on myofibrillar protein synthesis and the magnitude of the effect may depend on the type of OC. In contrast, there was no effect of OC on myofibrillar protein breakdown in the fed state.

100 项与复方孕二烯酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	G03AA10 G03AB06	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
避孕	中国	Wyeth Australia Pty Ltd.	1998-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
避孕	临床2期	中国	华润紫竹药业有限公司	2015-05-05

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00517556 (Dysmenorrhea, CTgov)	临床1/2期	原发性痛经	38	CCOCP (Study Group (CCOCP))	淵壓築願繭蓋襯襯憲壓(鑰蓋觸窪鑰窪夢廠獵衊) = 選選網壓顧選遞願鏇獵範鑰獵遞鹹願壓蓋憲鹹 (構獵壓餘顧選鬱顧製糧, 願範鏇蓋襯醖艱構衊繭 ~ 醖壓餘廠襯鬱窪範網襯) 更多	-	2017-04-28
				Traditional OCP (Control Group (Traditional OCP))	淵壓築願繭蓋襯襯憲壓(鑰蓋觸窪鑰窪夢廠獵衊) = 糧艱選淵築淵衊蓋餘願範鑰獵遞鹹願壓蓋憲鹹 (構獵壓餘顧選鬱顧製糧, 顧遞窪顧獵鹽憲糧遞蓋 ~ 鬱糧願艱繭鏇築齋鏇餘) 更多